Analytical Data
-
Gene name
HLA-A*02:01&B2M&CMV pp65(NLVPMVATV) Monomer
- Application
-
Alternative Names
HLA-A*01:01&B2M&CMV pp65 Complex
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&NLVPMVATV
-
Molecular Weight
43-48 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/CMV pp65 (NLVPMVATV) monomeric recombinant protein is critical in understanding immune responses to cytomegalovirus (CMV) infection, particularly in individuals with HLA-A*02:01 alleles, which are prevalent in various populations. CMV is a significant viral pathogen known to cause severe disease in immunocompromised patients, such as organ transplant recipients and those with HIV/AIDS. The pp65 protein is a major immunodominant antigen for CD8+ T cell responses in CMV infection. By developing a recombinant protein that includes the HLA-A*02:01 molecule, β2-microglobulin (B2M), and the specific epitope NLVPMVATV from CMV pp65, researchers can create a model to study the binding affinity, T cell receptor recognition, and overall immune response. This monomeric complex facilitates detailed immunological studies that can enhance our understanding of protective immunity against CMV. Furthermore, by evaluating how these components interact, scientists aim to inform vaccine development strategies, enhance the design of adoptive T cell therapies, and ultimately improve clinical outcomes for patients at risk of CMV-related diseases. The integration of structural biology and immunology in this research area underscores its potential to translate findings into therapeutic advances and improve management of CMV in vulnerable populations. As CMV remains a major challenge in clinical settings, this recombinant protein research is pivotal for enhancing our knowledge of T cell-mediated immune responses and facilitating effective interventions.
